CA2662831A1 - Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-.alpha.-d-mannopyranosyl-oxy)-phenyl] hexane - Google Patents

Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-.alpha.-d-mannopyranosyl-oxy)-phenyl] hexane Download PDF

Info

Publication number
CA2662831A1
CA2662831A1 CA002662831A CA2662831A CA2662831A1 CA 2662831 A1 CA2662831 A1 CA 2662831A1 CA 002662831 A CA002662831 A CA 002662831A CA 2662831 A CA2662831 A CA 2662831A CA 2662831 A1 CA2662831 A1 CA 2662831A1
Authority
CA
Canada
Prior art keywords
approximately
peak
medium peak
medium
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662831A
Other languages
English (en)
French (fr)
Inventor
Ewald M. Aydt
Remo Kranich
Karin Vollhardt
Gerhard Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revotar Biopharmaceuticals AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2662831A1 publication Critical patent/CA2662831A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002662831A 2006-09-08 2007-09-07 Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-.alpha.-d-mannopyranosyl-oxy)-phenyl] hexane Abandoned CA2662831A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06120399A EP1903049A1 (en) 2006-09-08 2006-09-08 Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane
EP06120399.8 2006-09-08
PCT/EP2007/059410 WO2008028966A1 (en) 2006-09-08 2007-09-07 Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyl-oxy)-phenyl] hexane

Publications (1)

Publication Number Publication Date
CA2662831A1 true CA2662831A1 (en) 2008-03-13

Family

ID=37478746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662831A Abandoned CA2662831A1 (en) 2006-09-08 2007-09-07 Crystalline forms of 1,6-bis [3-(3-carboxymethylphenyl)-4-(2-.alpha.-d-mannopyranosyl-oxy)-phenyl] hexane

Country Status (6)

Country Link
US (2) US20100144654A1 (https=)
EP (3) EP1903049A1 (https=)
JP (1) JP2010502682A (https=)
CN (1) CN101541821B (https=)
CA (1) CA2662831A1 (https=)
WO (1) WO2008028966A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1903049A1 (en) * 2006-09-08 2008-03-26 Revotar Biopharmaceuticals AG Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane
FR2929510B1 (fr) * 2008-04-02 2011-01-21 Lvmh Rech Utilisation d'au moins un glycoside d'alkyle en tant qu'agen qu'agent anti-vieillissement et/ou calmant des peaux sensibles dans des compositions cosmetiques, et methodes de soin cosmetique utilisant les dites compositions.
EP2380006A4 (en) * 2009-01-21 2012-05-16 Biocon Ltd PROCESS FOR DETERMINING THE SIROLIMUS STABILITY AND METHOD FOR PRODUCING ITS STABLE FORM
AU2011249843A1 (en) * 2010-05-07 2012-11-29 Revotar Biopharmaceuticals Ag Process for the preparation of Bimosiamose
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704596B2 (en) * 1995-06-29 1999-04-29 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
US5712387A (en) * 1996-05-20 1998-01-27 Texas Biotechnology Corporation High yield stereospecific mannosylation
US5919768A (en) * 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
GB9924990D0 (en) 1999-10-21 1999-12-22 Glaxo Group Ltd Medicaments
US20020132220A1 (en) * 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
EP1897533A1 (en) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1903049A1 (en) 2006-09-08 2008-03-26 Revotar Biopharmaceuticals AG Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyloxy)-phenyl] hexane
EP1958637A1 (en) * 2007-02-14 2008-08-20 Revotar Biopharmaceuticals AG Pharmaceutical composition for the treatment of IL-8 mediated diseases
WO2010115164A1 (en) 2009-04-03 2010-10-07 Medicis Pharmaceutical Corporation Topical compositions

Also Published As

Publication number Publication date
CN101541821A (zh) 2009-09-23
US8039601B1 (en) 2011-10-18
US20110257114A1 (en) 2011-10-20
EP1903049A1 (en) 2008-03-26
JP2010502682A (ja) 2010-01-28
WO2008028966A1 (en) 2008-03-13
EP2089407B1 (en) 2013-05-22
CN101541821B (zh) 2013-03-20
US20100144654A1 (en) 2010-06-10
EP2089407A1 (en) 2009-08-19
EP2607368A1 (en) 2013-06-26

Similar Documents

Publication Publication Date Title
EP2102224B2 (en) CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE
JP4226070B2 (ja) １−クロロ−４−（β−Ｄ−グルコピラノース−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶性形態、その調製方法及び薬物を調製するためのその使用
US8039601B1 (en) Crystalline forms of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)-phenyl] hexane
JP5091853B2 (ja) １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｒ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形、その調製方法及び薬剤を調製するための使用
TW201127849A (en) Method for the preparation of a crystalline form
KR20200016246A (ko) 질환의 예방 및 치료를 위한 화합물 및 이의 용도
CA3113956A1 (en) Galactoside inhibitor of galectins
TW201043637A (en) Steroid compound
WO2009064485A1 (en) Antioxidant flavonoid derivatives
EP3492484A1 (en) Novel galactoside inhibitor of galectins
CA2129140A1 (en) Lewis-type sugar chain derivative
WO2018014866A1 (zh) 达格列净中间体的晶型及其制备方法
CN100418535C (zh) 一种七叶皂苷及其制备方法
CN103608019B (zh) 抗肿瘤剂
JP3239191B2 (ja) 美白化粧品用成分の製造方法
WO1991006555A1 (fr) Derive nucleosidique
CN1226300C (zh) 一种布洛芬糖缀合物及其制备方法和应用
WO2009096737A2 (ko) 신규 유기 게르마늄 화합물 및 이를 유효성분으로 포함하는 조성물
JP2906978B2 (ja) 血糖降下剤
WO1999047542A1 (fr) Medicaments contenant en tant que principe actif des composes steroides glycosyles substitues en position 21
JPH04503681A (ja) 新規１―トリアコンタノール誘導体
EP3970797A1 (en) Anhydrous crystal of monosodium n-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexane carboxamide
CN108640958A (zh) 异苯并呋喃衍生物、其药物组合物和制剂以及用途
JP7140325B2 (ja) 化合物、抗アレルギー剤およびメディエーター遊離阻害剤
WO2000051959A1 (fr) Derives fluores de chalcone ou leurs sels, et medicaments contenant ces derives comme principe actif

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140909